Literature DB >> 9182838

Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation.

D E Wilkins1, C E Ng, G P Raaphorst.   

Abstract

PURPOSE: To investigate cell cycle pertubations in plateau-phase human ovarian carcinoma cells following treatment with cisplatin, low dose-rate irradiation (LDRI), or combined cisplatin and LDRI, in order to understand cell cycle mechanisms by which these two treatment modalities interact.
METHODS: Human ovarian carcinoma cells sensitive (A2780) and resistant (2780CP) to cisplatin were grown to plateau phase and given protracted cisplatin treatments (A2780 0.7 and 2 microg/ml; 2780CP 5 and 15 microg/ml) and/or LDRI (0.41 cGy/min). Cell cycle distribution following treatment was determined by two-parameter flow cytometry, based on bromodeoxyuridine (BrdU) uptake and DNA content using propidium iodide staining.
RESULTS: The cisplatin-sensitive A2780 cells exposed to cisplatin alone for up to 28 h showed depletion of the G1 fraction and accumulation in S-phase, although the percentage of S-phase cells actively incorporating BrdU dropped to almost zero. The cisplatin-resistant 2780CP cells exposed to cisplatin alone showed a G1 arrest when exposed to 15 microg/ml, but not when exposed to 5 microg/ml. LDRI alone caused little cell cycle redistribution different from controls in either cell line. When LDRI was combined with cisplatin, no significant cell cycle redistribution was observed, apart from a decline in the actively incorporating S-phase fraction.
CONCLUSIONS: Cisplatin caused A2780 cells to accumulate in nonincorporating S-phase, with no evidence of G1 arrest. Cisplatin-resistant 2780CP cells showed a G1 block when exposed to a high enough cisplatin concentration. This could indicate a mechanism of cisplatin resistance in these cells. LDRI alone or in combination with cisplatin did not result in significant cell cycle redistribution.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182838     DOI: 10.1007/s002800050641

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining.

Authors:  Heather J Boeckman; Kelly S Trego; John J Turchi
Journal:  Mol Cancer Res       Date:  2005-05       Impact factor: 5.852

2.  The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog.

Authors:  Guangan He; Jian Kuang; Abdul R Khokhar; Zahid H Siddik
Journal:  Gynecol Oncol       Date:  2011-05-18       Impact factor: 5.482

3.  Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links.

Authors:  Guangyu Zhu; Stephen J Lippard
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

4.  Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.

Authors:  P Liu; I S Kumar; S Brown; V Kannappan; P E Tawari; J Z Tang; W Jiang; A L Armesilla; J L Darling; W Wang
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

5.  The effect of sodium butyrate and cisplatin on expression of EMT markers.

Authors:  Alena Mrkvicova; Marcela Chmelarova; Eva Peterova; Radim Havelek; Ivana Baranova; Petra Kazimirova; Emil Rudolf; Martina Rezacova
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.